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“… as we know, there are known knowns; there are things we know we know. We also know 
there are known unknowns; that is to say we know there are some things we do not know. 
But there are also unknown unknowns -- the ones we don't know we don't know.” 
 Secretary of Defense Donald H. Rumsfeld, February 12, 2002[1] 
 
Copeland [2] suggests that there are currently enough known knowns about cannabis use 
and its consequences for us to develop suitable evidence-based and targeted cannabis-
related policies, treatment guidelines, and prevention and intervention strategies. As is 
apparent from the other commentaries [3-6], this is not a universally held opinion. For 
example, there known unknowns that are essential for evidence-based and targeted clinical 
practice and public health strategies which are discussed by Hammersley [3] (e.g., lack of a 
theory of dependence that fits cannabis using behaviour), Patton [4] (e.g., lack of knowledge 
of the predictive value of different indicators of use for health and developmental 
outcomes), and Andreasson [5] (e.g., lack of knowledge about the hidden population of 
cannabis users). All of the commentaries support the known known status of 
methodological limitations in the cannabis use literature [2-6]. 
Copeland, citing longitudinal studies, implies the association between cannabis use and 
psychosis is a known known [2]. However, as pointed out by Hammersley [3], the lack of any 
theory explaining how cannabis use might cause psychosis suggests that the nature of this 
relationship is a known unknown. Additionally, while longitudinal studies contribute to the 
determination of causality, this is only possible if confounding is adequately controlled, the 
cannabis data collected is appropriately detailed, and the assumptions on which the studies 
are based are accurate [7]. Meta-analytic studies are only as accurate as the studies on 
which they are based [3].  
Similarly, the inference that the relationship between high frequency of use and adverse 
outcomes is a known known [2] does not stand up once the methodological issues 
associated with frequency of use variables [4-7] are considered. The association between 
early onset of use and adverse outcomes also requires closer scrutiny because early onset of 
cannabis use is itself an outcome variable (or symptom) of adverse childhood experiences 
(e.g., neglect, abuse) [8]. Thus, another known unknown relates to what we actually assess 
when onset of use is employed as an independent variable to investigate adverse outcomes 
of use.  
Although cannabis usage rates appear to be declining or stabilising in Western countries 
[2,9], this does not mean that use is not relatively normalised among young people in these 
societies [10]. Cannabis use is typically initiated in the late teens or early twenties [11], thus, 
if we want to get a feel for how normalised cannabis use is we need to not only consider the 
recent usage statistics for 14-19 year olds (12.9% in 2007) cited by Copeland [2] but also 
those for 20-29 year olds (20.8% in 2007)[12]. Similarly, it is important to consider lifetime 
prevalence rates, which were 20.0% and 49.5%, respectively [12].  
Earleywine’s ‘elephant in the room’ (adverse outcomes for users associated with the 
illegality of cannabis) [6] also deserves attention. We would contend that, although seldom 
acknowledged, this is already known. If we are serious about reducing the harms of 
cannabis use, for individual users and society at large, we cannot ignore those harms 
associated with the illegality of use [6]. Correspondingly, it is concerning that the legal status 
of cannabis hinders our ability to understand the effects of cannabis use by limiting research 
options [5,6]. The prohibition debate should also include consideration of the harms to 
society that relate to our restricted ability to investigate the medicinal properties of 
cannabis, and the harms to those unable to use cannabis legally to alleviate suffering from 
diseases such as MS [13] and HIV [14]. 
As for the unknown unknowns, further research is always needed [3-5]. We hope other 
researchers, clinicians, policymakers, legislators, and users will join us in our quest to 
increase what is known about cannabis use and to develop sensible, evidence-based public 
health policies and legislation [3-6]. Transparency in this process, through open debate of 
what is known and unknown about cannabis use and its consequences [7], is essential if we 
are to move beyond the grass ceiling [4].      
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